Dear All, A huge announcement today backed by the combined power of the Gates Foundation, Novo Nordisk, and Wellcome! I am going to quote liberally from their materials: Responding to the problem of AMR, “… the Novo Nordisk Foundation (NNF), Wellcome, and the Gates Foundation (GF) are jointly launching a new initiative, Gram-Negative Antibiotic Discovery

Dear All, Three things for today along with some great acronyms! To start, we have an announcement of the first ever National One Health Framework to Address Zoonotic Diseases and Advance Public Health Preparedness in the United States (NOHF-Zoonoses) (website, .pdf of the framework). As a reminder, a zoonosis is an infection that jumps from

Dear All, I wrote in the 1 Dec 2024 newsletter about the excellent paper by Baraldi et al. that introduced us to the 6 possible meaning of “lack of access.” Since that newsletter, a bit of back-and-forth has produced a UNSLAP as a pronounceable acronym for the 6 meanings: (U)nregistered, (N)ever registered (or, not registered),

Dear All, I’ve written before about the Vivli AMR Surveillance Data Challenge that seeks creative ways to reuse MICs from surveillance datasets (the 24 April 2023 newsletter covered the 2023 Challenge; the 15 June 2024 newsletter flagged the 2024 Challenge).  As a reminder, Vivli is a clinical data sharing platform that was created in 2013 from a

Dear All, Just released, the 2026 NIAID DMID Omnibus Broad Agency Announcement (HHS-NIH-NIAID-BAA2025-1) seeks applications for projects to treat, prevent, and diagnose bacterial, fungal, and viral infections. Of interest for this community, the BAA’s Research Area 001 seeks applications by 21 Feb 2025 for bacterial and fungal projects across thee topics (see below my signature for

Dear All, I was delighted to learn today that NIAID has released RFA-AI-24-069, a notice of funding opportunity (NOFO) soliciting applications to establish Centers for Accelerating Phage Therapy to Combat ESKAPE Pathogens (CAPT-CEP). The CAPT-CEPs will focus on developing preclinical assays, tools, and models for robust phage therapy R&D and advancing phage clinical research. Applications are due

Dear All (and with thanks to Patricia Bradford for leading on this newsletter), Did you know you can access raw datasets of antimicrobial susceptibility surveillance data that have been generated by the pharmaceutical industry? Indeed such datasets exist and we’d like to ensure everyone is aware of their availability and potential! Background: The 20 Oct